Supportive Care Delivered by Telemedicine to Cancer Patients at Home

Not Applicable

Completed

• Conditions: Supportive Care; Cancer

• Registration Number: NCT04136340
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

This study will test whether supportive care follow-up delivered to cancer patients at home by telemedicine ("virtual" medical visits using telecommunications technologies) is as effective as in-person supportive care visits in the clinic.

Detailed Description

The protocol was developed and initially implemented when the standard of care for Supportive Care (and oncology) follow-up at MSK was in-person visiting and home telemedicine was only in an early stage of use at the institution. During the COVID-19 crisis, all outpatient Supportive Care visits and most oncology visits at MSK have been handled via telemedicine to protect patient (and staff) safety.

Study Timeline

• Study First Submitted: 2019-10-21
• Study First Submitted QC: 2019-10-22
• Study First Posted: 2019-10-23
• Study Start: 2019-10-24
• Status Verified: 2025-07
• Primary Completion: 2025-07-03
• Study Completion: 2025-07-03
• Last Update Submitted: 2025-07-07
• Last Update Posted: 2025-07-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• age 18 years or older
• solid tumor of any type
• completed an initial in-person clinic visit (i.e. an IR/NV or AFX visit) at Rockefeller Outpatient Pavilion with Dr. Saldivar, Dr. Martin, Supportive Care physicians, or Andrea Dolan, a Supportive Care nurse practitioner
• planned for Supportive Care Service follow-up visits, but none yet completed
• enrolled on the MyMSK secure online patient portal and have access to the portal off site of MSK campuses
• resident of New York or New Jersey or Connecticut (clinicians may not be licensed in other states, as would be required for televisits to patients there)

Exclusion Criteria

• Patients and informal caregivers who cannot communicate with clinicians/respond to instruments in English without the use of an interpreter

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Health-Related Quality of Life: FACT-G	Week 14	will be used to quantify health-related quality of life at baseline and Week 14 after randomization. All items in the FACT-G use a 5-point scale (0=Not at all to 4=Very much) and the total score sums four subscales and ranges from 0-108 (higher=better QoL). Change in total score at Week 14 after randomization vs. baseline.

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States